In the future, disaggregase chaperones such as Hsp110 may be a broad-acting therapeutic target for the protein aggregates that occur in a variety of neurodegenerative diseases, most prominently Alzheimer's and Parkinson's disease (Shorter, 2016). Here, HSPH1 is linked to neurodegenerative disease.